BAP1 and mesothelioma: In a drug screening assay, a mesothelioma cell line harboring a BAP1 mutation that did not have mutations in any of the FGFR genes but showed functional overexpression of the FGFR pathway was shown to be sensitive, both in vitro and in vivo, to the inhibition of the FGFR pathway mediated by the irreversible FGFR inhibitor AZ4547 [80].